Header Logo

Carl Maki

TitleProfessor
InstitutionRush University, Rush Medical College
DepartmentAnatomy and Cell Biology
AddressChicago IL 60612
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus number is 35561716200.
    My NIH COMMONS name is CGMAKI.

    My Faculty Profile at Rush University Medical Center:
    https://www.rushu.rush.edu/faculty/carl-maki-phd

    My Laboratory:
    https://www.rushu.rush.edu/research/departmental-research/cell-molecular-medicine-research/laboratory-carl-maki-phd

    My NCBI Bibliography:
    https://www.ncbi.nlm.nih.gov/pubmed/?term=Maki+CG

    My Scopus:
    https://www.scopus.com/authid/detail.uri?authorId=35561716200

    Education:
    PhD, Kansas State University

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Duan L, Tadi MJ, Maki CG. CSE1L is a negative regulator of the RB-DREAM pathway in p53 wild-type NSCLC and can be targeted using an HDAC1/2 inhibitor. Sci Rep. 2023 09 27; 13(1):16271. PMID: 37759078.
      Citations:    
    2. Duan L, Calhoun SJ, Perez RE, Macias V, Mir F, Gattuso P, Maki CG. Prolylcarboxypeptidase promotes IGF1R/HER3 signaling and is a potential target to improve endocrine therapy response in estrogen receptor positive breast cancer. Cancer Biol Ther. 2022 Dec 31; 23(1):1-10. PMID: 36332175.
      Citations:    
    3. Duan L, Perez RE, Calhoun S, Maki CG. Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15. Cancer Biol Ther. 2022 12 31; 23(1):65-75. PMID: 35100078.
      Citations:    
    4. Kumar S, Das S, Sun J, Huang Y, Singh SK, Srivastava P, Sondarva G, Nair RS, Viswakarma N, Ganesh BB, Duan L, Maki CG, Hoskins K, Danciu O, Rana B, Li S, Rana A. Mixed lineage kinase 3 and CD70 cooperation sensitize trastuzumab-resistant HER2+ breast cancer by ceramide-loaded nanoparticles. Proc Natl Acad Sci U S A. 2022 09 20; 119(38):e2205454119. PMID: 36095190.
      Citations:    
    5. Duan L, Perez RE, Calhoun S, Maki CG. Author Correction: RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC. Sci Rep. 2022 Mar 16; 12(1):4525. PMID: 35296774.
      Citations:    
    6. Calhoun S, Duan L, Maki CG. Acetyl-CoA synthetases ACSS1 and ACSS2 are 4-hydroxytamoxifen responsive factors that promote survival in tamoxifen treated and estrogen deprived cells. Transl Oncol. 2022 May; 19:101386. PMID: 35263700.
      Citations:    
    7. Duan L, Calhoun S, Perez RE, Macias V, Mir F, Pergande MR, Gattuso P, Borgia JA, Maki CG. Prolyl Carboxypeptidase Maintains Receptor Tyrosine Kinase Signaling and Is a Potential Therapeutic Target in Triple Negative Breast Cancer. Cancers (Basel). 2022 Jan 31; 14(3). PMID: 35159006.
      Citations:    
    8. Duan L, Calhoun S, Shim D, Perez RE, Blatter LA, Maki CG. Corrigendum to 'Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells'. J Mol Cell Biol. 2022 Jan 29; 13(12):922. PMID: 35092683.
      Citations:    
    9. Duan L, Perez RE, Calhoun S, Maki CG. RBL2/DREAM-mediated repression of the Aurora kinase A/B pathway determines therapy responsiveness and outcome in p53 WT NSCLC. Sci Rep. 2022 01 20; 12(1):1049. PMID: 35058503.
      Citations:    
    10. Shim D, Duan L, Maki CG. Erratum: P53-regulated autophagy and its impact on drug resistance and cell fate. Cancer Drug Resist. 2021; 4(4):903. PMID: 35582378.
      Citations:    
    11. Duan L, Calhoun S, Shim D, Perez RE, Blatter LA, Maki CG. Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells. J Mol Cell Biol. 2021 09 11; 13(6):433-444. PMID: 33755174.
      Citations:    
    12. Shim D, Duan L, Maki CG. P53-regulated autophagy and its impact on drug resistance and cell fate. Cancer Drug Resist. 2021; 4:85-95. PMID: 34532654.
      Citations:    
    13. Perez RE, Calhoun S, Shim D, Levenson VV, Duan L, Maki CG. Prolyl endopeptidase inhibitor Y-29794 blocks the IRS1-AKT-mTORC1 pathway and inhibits survival and in vivo tumor growth of triple-negative breast cancer. Cancer Biol Ther. 2020 11 01; 21(11):1033-1040. PMID: 33044914.
      Citations:    
    14. Duan L, Perez RE, Lai X, Chen L, Maki CG. The histone demethylase JMJD2B is critical for p53-mediated autophagy and survival in Nutlin-treated cancer cells. J Biol Chem. 2019 06 07; 294(23):9186-9197. PMID: 31036564.
      Citations:    
    15. Duan L, Perez RE, Chastain PD, Mathew MT, Bijukumar DR, Maki CG. JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells. Oncogene. 2019 07; 38(28):5643-5657. PMID: 30967636.
      Citations:    
    16. Duan L, Perez RE, Maki CG. Alpha ketoglutarate levels, regulated by p53 and OGDH, determine autophagy and cell fate/apoptosis in response to Nutlin-3a. Cancer Biol Ther. 2019; 20(3):252-260. PMID: 30289354.
      Citations:    
    17. Duan L, Perez RE, Chen L, Blatter LA, Maki CG. p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a. J Mol Cell Biol. 2018 08 01; 10(4):331-340. PMID: 29190376.
      Citations:    
    18. Zhou Y, Perez RE, Duan L, Maki CG. DZNep represses Bcl-2 expression and modulates apoptosis sensitivity in response to Nutlin-3a. Cancer Biol Ther. 2018 06 03; 19(6):465-474. PMID: 29394130.
      Citations:    
    19. Davaadelger B, Perez RE, Zhou Y, Duan L, Gitelis S, Maki CG. The IGF-1R/AKT pathway has opposing effects on Nutlin-3a-induced apoptosis. Cancer Biol Ther. 2017 Nov 02; 18(11):895-903. PMID: 28696156.
      Citations:    
    20. Duan L, Maki CG. The IGF-1R/AKT pathway determines cell fate in response to p53. Transl Cancer Res. 2016 Dec; 5(6):664-675. PMID: 28966916.
      Citations:    
    21. Davaadelger B, Duan L, Perez RE, Gitelis S, Maki CG. Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor. Oncotarget. 2016 May 10; 7(19):27511-26. PMID: 27050276.
      Citations:    
    22. Perez RE, Shen H, Duan L, Kim RH, Kim T, Park NH, Maki CG. Modeling the Etiology of p53-mutated Cancer Cells. J Biol Chem. 2016 May 06; 291(19):10131-47. PMID: 27022024.
      Citations:    
    23. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena A, Adachi H, Adams CM, Adams PD, Adeli K, Adhihetty PJ, Adler SG, Agam G, Agarwal R, Aghi MK, Agnello M, Agostinis P, Aguilar PV, Aguirre-Ghiso J, Airoldi EM, Ait-Si-Ali S, Akematsu T, Akporiaye ET, Al-Rubeai M, Albaiceta GM, Albanese C, Albani D, Albert ML, Aldudo J, Alg?l H, Alirezaei M, Alloza I, Almasan A, Almonte-Beceril M, Alnemri ES, Alonso C, Altan-Bonnet N, Altieri DC, Alvarez S, Alvarez-Erviti L, Alves S, Amadoro G, Amano A, Amantini C, Ambrosio S, Amelio I, Amer AO, Amessou M, Amon A, An Z, Anania FA, Andersen SU, Andley UP, Andreadi CK, Andrieu-Abadie N, Anel A, Ann DK, Anoopkumar-Dukie S, Antonioli M, Aoki H, Apostolova N, Aquila S, Aquilano K, Araki K, Arama E, Aranda A, Araya J, Arcaro A, Arias E, Arimoto H, Ariosa AR, Armstrong JL, Arnould T, Arsov I, Asanuma K, Askanas V, Asselin E, Atarashi R, Atherton SS, Atkin JD, Attardi LD, Auberger P, Auburger G, Aurelian L, Autelli R, Avagliano L, Avantaggiati ML, Avrahami L, Awale S, Azad N, Bachetti T, Backer JM, Bae DH, Bae JS, Bae ON, Bae SH, Baehrecke EH, Baek SH, Baghdiguian S, Bagniewska-Zadworna A, Bai H, Bai J, Bai XY, Bailly Y, Balaji KN, Balduini W, Ballabio A, Balzan R, Banerjee R, B?nhegyi G, Bao H, Barbeau B, Barrachina MD, Barreiro E, Bartel B, Bartolom? A, Bassham DC, Bassi MT, Bast RC, Basu A, Batista MT, Batoko H, Battino M, Bauckman K, Baumgarner BL, Bayer KU, Beale R, Beaulieu JF, Beck GR, Becker C, Beckham JD, B?dard PA, Bednarski PJ, Begley TJ, Behl C, Behrends C, Behrens GM, Behrns KE, Bejarano E, Belaid A, Belleudi F, B?nard G, Berchem G, Bergamaschi D, Bergami M, Berkhout B, Berliocchi L, Bernard A, Bernard M, Bernassola F, Bertolotti A, Bess AS, Besteiro S, Bettuzzi S, Bhalla S, Bhattacharyya S, Bhutia SK, Biagosch C, Bianchi MW, Biard-Piechaczyk M, Billes V, Bincoletto C, Bingol B, Bird SW, Bitoun M, Bjedov I, Blackstone C, Blanc L, Blanco GA, Blomhoff HK, Boada-Romero E, B?ckler S, Boes M, Boesze-Battaglia K, Boise LH, Bolino A, Boman A, Bonaldo P, Bordi M, Bosch J, Botana LM, Botti J, Bou G, Bouch? M, Bouchecareilh M, Boucher MJ, Boulton ME, Bouret SG, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady N, Braga VM, Brancolini C, Braus GH, Bravo-San Pedro JM, Brennan LA, Bresnick EH, Brest P, Bridges D, Bringer MA, Brini M, Brito GC, Brodin B, Brookes PS, Brown EJ, Brown K, Broxmeyer HE, Bruhat A, Brum PC, Brumell JH, Brunetti-Pierri N, Bryson-Richardson RJ, Buch S, Buchan AM, Budak H, Bulavin DV, Bultman SJ, Bultynck G, Bumbasirevic V, Burelle Y, Burke RE, Burmeister M, B?tikofer P, Caberlotto L, Cadwell K, Cahova M, Cai D, Cai J, Cai Q, Calatayud S, Camougrand N, Campanella M, Campbell GR, Campbell M, Campello S, Candau R, Caniggia I, Cantoni L, Cao L, Caplan AB, Caraglia M, Cardinali C, Cardoso SM, Carew JS, Carleton LA, Carlin CR, Carloni S, Carlsson SR, Carmona-Gutierrez D, Carneiro LA, Carnevali O, Carra S, Carrier A, Carroll B, Casas C, Casas J, Cassinelli G, Castets P, Castro-Obregon S, Cavallini G, Ceccherini I, Cecconi F, Cederbaum AI, Ce?a V, Cenci S, Cerella C, Cervia D, Cetrullo S, Chaachouay H, Chae HJ, Chagin AS, Chai CY, Chakrabarti G, Chamilos G, Chan EY, Chan MT, Chandra D, Chandra P, Chang CP, Chang RC, Chang TY, Chatham JC, Chatterjee S, Chauhan S, Che Y, Cheetham ME, Cheluvappa R, Chen CJ, Chen G, Chen GC, Chen G, Chen H, Chen JW, Chen JK, Chen M, Chen M, Chen P, Chen Q, Chen Q, Chen SD, Chen S, Chen SS, Chen W, Chen WJ, Chen WQ, Chen W, Chen X, Chen YH, Chen YG, Chen Y, Chen Y, Chen Y, Chen YJ, Chen YQ, Chen Y, Chen Z, Chen Z, Cheng A, Cheng CH, Cheng H, Cheong H, Cherry S, Chesney J, Cheung CH, Chevet E, Chi HC, Chi SG, Chiacchiera F, Chiang HL, Chiarelli R, Chiariello M, Chieppa M, Chin LS, Chiong M, Chiu GN, Cho DH, Cho SG, Cho WC, Cho YY, Cho YS, Choi AM, Choi EJ, Choi EK, Choi J, Choi ME, Choi SI, Chou TF, Chouaib S, Choubey D, Choubey V, Chow KC, Chowdhury K, Chu CT, Chuang TH, Chun T, Chung H, Chung T, Chung YL, Chwae YJ, Cianfanelli V, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016; 12(1):1-222. PMID: 26799652.
      Citations:    
    24. Duan L, Perez RE, Davaadelger B, Dedkova EN, Blatter LA, Maki CG. p53-regulated autophagy is controlled by glycolysis and determines cell fate. Oncotarget. 2015 Sep 15; 6(27):23135-56. PMID: 26337205.
      Citations:    
    25. Davaadelger B, Shen H, Maki CG. Novel roles for p53 in the genesis and targeting of tetraploid cancer cells. PLoS One. 2014; 9(11):e110844. PMID: 25380055.
      Citations:    
    26. Duan L, Danzer B, Levenson VV, Maki CG. Critical roles for nitric oxide and ERK in the completion of prosurvival autophagy in 4OHTAM-treated estrogen receptor-positive breast cancer cells. Cancer Lett. 2014 Oct 28; 353(2):290-300. PMID: 25069039.
      Citations:    
    27. Duan L, Ying G, Danzer B, Perez RE, Shariat-Madar Z, Levenson VV, Maki CG. The prolyl peptidases PRCP/PREP regulate IRS-1 stability critical for rapamycin-induced feedback activation of PI3K and AKT. J Biol Chem. 2014 Aug 01; 289(31):21694-705. PMID: 24936056.
      Citations:    
    28. Lu Y, Gitelis S, Lei G, Ding M, Maki C, Mira RR, Zheng Q. Research findings working with the p53 and Rb1 targeted osteosarcoma mouse model. Am J Cancer Res. 2014; 4(3):234-44. PMID: 24959378.
      Citations:    
    29. Duan L, Perez RE, Hansen M, Gitelis S, Maki CG. Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1. Cancer Biol Ther. 2014; 15(12):1600-12. PMID: 25482935.
      Citations:    
    30. Shen H, Perez RE, Davaadelger B, Maki CG. Two 4N cell-cycle arrests contribute to cisplatin-resistance. PLoS One. 2013; 8(4):e59848. PMID: 23560058.
      Citations:    
    31. Aziz MH, Shen H, Maki CG. Glucocorticoid receptor activation inhibits p53-induced apoptosis of MCF10Amyc cells via induction of protein kinase Ce. J Biol Chem. 2012 Aug 24; 287(35):29825-36. PMID: 22773829.
      Citations:    
    32. Aziz MH, Shen H, Maki CG. Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3. Oncogene. 2011 Nov 17; 30(46):4678-86. PMID: 21643018.
      Citations:    
    33. Shen H, Maki CG. Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr Pharm Des. 2011; 17(6):560-8. PMID: 21391906.
      Citations:    
    34. Shen H, Maki CG. p53 and p21(Waf1) are recruited to distinct PML-containing nuclear foci in irradiated and Nutlin-3a-treated U2OS cells. J Cell Biochem. 2010 Dec 01; 111(5):1280-90. PMID: 20803550.
      Citations:    
    35. Maki CG. Decision-making by p53 and mTOR. Aging (Albany NY). 2010 Jun; 2(6):324-6. PMID: 20603526.
      Citations:    
    36. Shen H, Maki CG. Persistent p21 expression after Nutlin-3a removal is associated with senescence-like arrest in 4N cells. J Biol Chem. 2010 Jul 23; 285(30):23105-14. PMID: 20489208.
      Citations:    
    37. Moran DM, Maki CG. Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells. Mol Cancer Ther. 2010 Apr; 9(4):895-905. PMID: 20371712.
      Citations:    
    38. Moran DM, Shen H, Maki CG. Puromycin-based vectors promote a ROS-dependent recruitment of PML to nuclear inclusions enriched with HSP70 and Proteasomes. BMC Cell Biol. 2009 May 01; 10:32. PMID: 19409099.
      Citations:    
    39. Shen H, Moran DM, Maki CG. Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells. Cancer Res. 2008 Oct 15; 68(20):8260-8. PMID: 18922897.
      Citations:    
    40. Moran DM, Gawlak G, Jayaprakash MS, Mayar S, Maki CG. Geldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells. Oncogene. 2008 Sep 18; 27(42):5567-77. PMID: 18504430.
      Citations:    
    41. Nie L, Sasaki M, Maki CG. Regulation of p53 nuclear export through sequential changes in conformation and ubiquitination. J Biol Chem. 2007 May 11; 282(19):14616-25. PMID: 17371868.
      Citations:    
    42. Sasaki M, Nie L, Maki CG. MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation. J Biol Chem. 2007 May 11; 282(19):14626-34. PMID: 17363365.
      Citations:    
    43. Zhang L, Nie L, Maki CG. P53 and p73 differ in their ability to inhibit glucocorticoid receptor (GR) transcriptional activity. Mol Cancer. 2006 Dec 06; 5:68. PMID: 17150106.
      Citations:    
    44. Maki CG. P53 gene alterations identified in classical Hodgkin's lymphoma cell lines. Leuk Lymphoma. 2006 Sep; 47(9):1734-5. PMID: 17064981.
      Citations:    
    45. Inoue T, Wu L, Stuart J, Maki CG. Control of p53 nuclear accumulation in stressed cells. FEBS Lett. 2005 Sep 12; 579(22):4978-84. PMID: 16115632.
      Citations:    
    46. Zhu H, Nie L, Maki CG. Cdk2-dependent Inhibition of p21 stability via a C-terminal cyclin-binding motif. J Biol Chem. 2005 Aug 12; 280(32):29282-8. PMID: 15964852.
      Citations:    
    47. Wu L, Zhu H, Nie L, Maki CG. A link between p73 transcriptional activity and p73 degradation. Oncogene. 2004 May 13; 23(22):4032-6. PMID: 15021899.
      Citations:    
    48. Zhu H, Wu L, Maki CG. MDM2 and promyelocytic leukemia antagonize each other through their direct interaction with p53. J Biol Chem. 2003 Dec 05; 278(49):49286-92. PMID: 14507915.
      Citations:    
    49. Wei X, Yu ZK, Ramalingam A, Grossman SR, Yu JH, Bloch DB, Maki CG. Physical and functional interactions between PML and MDM2. J Biol Chem. 2003 Aug 01; 278(31):29288-97. PMID: 12759344.
      Citations:    
    50. Jardine LJ, Maki CG. Stability and ubiquitination of the tumor suppressor protein p53. Methods Mol Biol. 2003; 223:27-38. PMID: 12777718.
      Citations:    
    51. Ohteki T, Suzue K, Maki C, Ota T, Koyasu S. Critical role of IL-15-IL-15R for antigen-presenting cell functions in the innate immune response. Nat Immunol. 2001 Dec; 2(12):1138-43. PMID: 11702064.
      Citations:    
    52. Inoue T, Geyer RK, Howard D, Yu ZK, Maki CG. MDM2 can promote the ubiquitination, nuclear export, and degradation of p53 in the absence of direct binding. J Biol Chem. 2001 Nov 30; 276(48):45255-60. PMID: 11572869.
      Citations:    
    53. Ohteki T, Maki C, Koyasu S. Overexpression of Bcl-2 differentially restores development of thymus-derived CD4-8+ T cells and intestinal intraepithelial T cells in IFN-regulatory factor-1-deficient mice. J Immunol. 2001 Jun 01; 166(11):6509-13. PMID: 11359801.
      Citations:    
    54. Tasheva ES, Maki CG, Conrad AH, Conrad GW. Transcriptional activation of bovine mimecan by p53 through an intronic DNA-binding site. Biochim Biophys Acta. 2001 Feb 16; 1517(3):333-8. PMID: 11342211.
      Citations:    
    55. Inoue T, Geyer RK, Yu ZK, Maki CG. Downregulation of MDM2 stabilizes p53 by inhibiting p53 ubiquitination in response to specific alkylating agents. FEBS Lett. 2001 Feb 16; 490(3):196-201. PMID: 11223035.
      Citations:    
    56. Yu ZK, Geyer RK, Maki CG. MDM2-dependent ubiquitination of nuclear and cytoplasmic P53. Oncogene. 2000 Nov 30; 19(51):5892-7. PMID: 11127820.
      Citations:    
    57. Geyer RK, Yu ZK, Maki CG. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol. 2000 Sep; 2(9):569-73. PMID: 10980696.
      Citations:    
    58. Geyer RK, Nagasawa H, Little JB, Maki CG. Role and regulation of p53 during an ultraviolet radiation-induced G1 cell cycle arrest. Cell Growth Differ. 2000 Mar; 11(3):149-56. PMID: 10768862.
      Citations:    
    59. Alarc?n R, Koumenis C, Geyer RK, Maki CG, Giaccia AJ. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. Cancer Res. 1999 Dec 15; 59(24):6046-51. PMID: 10626788.
      Citations:    
    60. Ohteki T, Fukao T, Suzue K, Maki C, Ito M, Nakamura M, Koyasu S. Interleukin 12-dependent interferon gamma production by CD8alpha+ lymphoid dendritic cells. J Exp Med. 1999 Jun 21; 189(12):1981-6. PMID: 10377194.
      Citations:    
    61. Maki CG. Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2. J Biol Chem. 1999 Jun 04; 274(23):16531-5. PMID: 10347217.
      Citations:    
    62. Nagasawa H, Keng P, Maki C, Yu Y, Little JB. Absence of a radiation-induced first-cycle G1-S arrest in p53+ human tumor cells synchronized by mitotic selection. Cancer Res. 1998 May 01; 58(9):2036-41. PMID: 9581850.
      Citations:    
    63. Maki CG, Howley PM. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol Cell Biol. 1997 Jan; 17(1):355-63. PMID: 8972216.
      Citations:    
    64. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 1996 Jun 01; 56(11):2649-54. PMID: 8653711.
      Citations:    
    65. Nagasawa H, Li CY, Maki CG, Imrich AC, Little JB. Relationship between radiation-induced G1 phase arrest and p53 function in human tumor cells. Cancer Res. 1995 May 01; 55(9):1842-6. PMID: 7728750.
      Citations:    
    66. Maki CG, Rhoads DD, Diaz JJ, Roufa DJ. A Drosophila ribosomal protein functions in mammalian cells. Mol Cell Biol. 1990 Sep; 10(9):4524-8. PMID: 2388616.
      Citations:    
    67. Brown SJ, Jewell A, Maki CG, Roufa DJ. A cDNA encoding human ribosomal protein S24. Gene. 1990 Jul 16; 91(2):293-6. PMID: 2210388.
      Citations:    
    68. Maki C, Rhoads DD, Stewart MJ, Van Slyke B, Roufa DJ. The Drosophila melanogaster RPS17 gene encoding ribosomal protein S17. Gene. 1989 Jul 15; 79(2):289-98. PMID: 2507396.
      Citations:    
    Maki's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (346)
    Explore
    _
    Co-Authors (5)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _